{
    "Trade/Device Name(s)": [
        "VITEK 2 AST-GN Ciprofloxacin",
        "VITEK 2 AST-Gram Negative Ciprofloxacin"
    ],
    "Submitter Information": "bioM\u00e9rieux, Inc.",
    "510(k) Number": "K214023",
    "Predicate Device Reference 510(k) Number(s)": [
        "K191766"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON",
        "LTT",
        "LTW"
    ],
    "Summary Letter Date": "December 21, 2021",
    "Summary Letter Received Date": "December 22, 2021",
    "Submission Date": "December 21, 2021",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Ciprofloxacin"
    ],
    "Specimen Type(s)": [
        "Gram negative bacilli isolates",
        "Clinical isolates"
    ],
    "Specimen Container(s)": [
        "Saline suspension"
    ],
    "Instrument(s)/Platform(s)": [
        "VITEK 2",
        "VITEK 2 Compact"
    ],
    "Method(s)/Technology(ies)": [
        "Automated quantitative antimicrobial susceptibility testing",
        "Microdilution minimum inhibitory concentration (MIC) technique"
    ],
    "Methodologies": [
        "MIC determination",
        "Growth Pattern Analysis"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Panel",
        "Card"
    ],
    "Document Summary": "FDA 510(k) summary for VITEK 2 AST-GN Ciprofloxacin antimicrobial susceptibility panel using automated MIC determination on VITEK 2 systems",
    "Indications for Use Summary": "Quantitative in vitro antimicrobial susceptibility test for Gram-negative bacilli using VITEK 2 systems to aid in determination of susceptibility to ciprofloxacin.",
    "fda_folder": "Microbiology"
}